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Abstract
Diabetes is considered to be a risk factor in Alzheimer’s disease (AD) pathogenesis. Although 
recent evidence indicates that diabetes exaggerates pathologic features of AD, the underlying 
mechanisms are not well understood. To determine whether mitochondrial perturbation is 
associated with the contribution of diabetes to AD progression, we characterized mouse models of 
streptozotocin (STZ)-induced type 1 diabetes and transgenic AD mouse models with diabetes. 
Brains from mice with STZ-induced diabetes revealed a significant increase of cyclophilin D 
(CypD) expression, reduced respiratory function, and decreased hippocampal long-term 
potentiation (LTP); these animals had impaired spatial learning and memory. Hyperglycemia 
exacerbated the upregulation of CypD, mitochondrial defects, synaptic injury, and cognitive 
dysfunction in the brains of transgenic AD mice overexpressing amyloid-β as shown by decreased 
mitochondrial respiratory complex I and IV enzyme activity and greatly decreased mitochondrial 
respiratory rate. Concomitantly, hippocampal LTP reduction and spatial learning and memory 
decline, two early pathologic indicators of AD, were enhanced in the brains of diabetic AD mice. 
Our results suggest that the synergistic interaction between effects of diabetes and AD on 
mitochondria may be responsible for brain dysfunction that is in common in both diabetes and 
AD.
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Alzheimer’s disease (AD) is an age-dependent neurodegenerative disorder functionally 
characterized by progressive cognitive decline. The primary pathological alterations in AD 
in brain parenchyma are progressive accumulation of amyloid-β peptide (Aβ) derived from 
amyloid-β protein precursor (AβPP) and neurofibrillary tangles derived from abnormal 
phosphorylation of tau protein [1, 2]. Aβ is formed after sequential cleavage of AβPP and its 
most abundant isoforms are Aβ40 and Aβ42. Initially, Aβ products are non-fibrillary and 
soluble, which can directly affect many intracellular components to induce neuronal 
malfunction. Among intracellular targets of Aβ, mitochondria play a central role in Aβ-
mediated toxicity in synaptic injury, cognitive decline, and neuronal loss [3–15]. 
Accumulation of Aβ in AD patient brain and several transgenic mouse models of AD that 
overexpress Aβ progressively induce the increase of cyclophilin D (CypD), a critical 
component of mitochondrial permeable transition pore (mPTP), mitochondrial respiratory 
chain impairment, and energy failure. Interaction of Aβ with mitochondrial proteins, such as 
amyloid-binding alcohol dehydrogenase (ABAD) [4, 15–18] and CypD [11,19, 20], 
exacerbates Aβ-induced mitochondrial respiratory complex enzyme defects, synaptic 
plasticity impairment, and learning and memory decline. Thus, CypD and its associated 
mitochondrial function play a critical role in AD progression.
Both AD and diabetes are prevalent in elderly patients. Diabetes is a disorder of glucose 
metabolism characterized by perturbation of the insulin-signaling pathway, which results in 
hyperglycemia. These disturbances result from hypoinsulinemia diabetes due to impaired 
production of insulin in the case of type 1 diabetes, or from insulin resistance in type 2 
diabetes. Diabetes is a chronic disease with multiple severe complications and affects an 
estimated 25.8 million patients in the United States, according to the report in 2011 National 
Diabetes Fact sheet of the United States Centers for Disease Control and Prevention. In 
addition to the well-known adverse effects of diabetes on the cardiovascular and peripheral 
nervous systems, diabetes can also causes complications in the central nervous system 
(CNS) leading to ischemic stroke, episodic memory impairment [21], and synaptic plasticity 
deficit [22–30]. Synaptic dysfunction and learning and memory deficit, common to AD, 
have been observed in diabetic patients; in addition, many other features of AD pathology 
are identified in diabetic subjects. For example, elevated oxidative stress and impaired 
mitochondrial respiratory enzyme activity is often seen in diabetes in a variety of cell types 
including islet cells [31], hepatocytes [32], skeletal muscle cells [33, 34], blood 
mononuclear cells [35], endothelial cells [36], and dorsal root ganglion neurons [37, 38]. 
Mitochondrial dysfunction is also suggested to be a causative factor in the development of 
insulin resistance in skeletal muscle cells and hyperglycemia in type 2 diabetes [39, 40]. 
Compared to other cells, neurons are morphologically quite complicated and more 
susceptible to mitochondrial dysfunction because the neuronal transmission is tightly 
regulated by energy homeostasis in synapses. Mitochondrial alterations in hypothalamus 
have recently been identified as a control mechanism for food intake and energy 
expenditure, which in turn causes diet-induced obesity and diabetes [41]. Regardless 
whether mitochondrial dysfunction is a cause or a consequence of diabetes, we believe 
mitochondria play a critical role in diabetes-induced brain dysfunction.
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Recent epidemiological studies support a link between diabetes and AD in elderly patients 
[42]. A number of studies associate diabetes mellitus with AD pathogenesis [43–46]; indeed, 
it is considered a potential risk factor for developing AD [47]. Diabetes exacerbates features 
of AD pathology and learning and memory deficits in experimentally induced diabetes in 
mouse models of AD [46, 48–50]. However, the mechanisms underlying diabetes-induced 
synaptic dysfunction are not clear.
Mitochondrial dysfunction is critical to the development and progression of AD [3–15]. As 
the mitochondria are particularly affected by hyperglycemia in diabetes [31–38] and 
mitochondria play a key role in supporting synaptic plasticity, one of the mechanisms of 
learning and memory, [51, 52], we induced type 1 diabetes in transgenic AD mice over-
expressing human Aβ (mAβPP mice) to determine whether mitochondrial perturbation is 
associated with the contribution of diabetes to AD progression.
MATERIALS AND METHODS
Animals
All studies were performed using the well-characterized transgenic mAβPP mouse model, 
which overexpresses hAβPP that encodes the hAβPP751-, and hAβPP770-bearing mutations 
of human AD (V717F, K670N, and M671L) and the control wild-type (WT) mice. 
Transgenic lines were maintained by crossing mAβPP transgenic mice with non-transgenic 
wild type (WT) C57BL/6 breeders. Animals were housed up to five per cage with free 
access to food and water and maintained in a vivarium proved by the American Association 
for the Accreditation of Laboratory Animal Care. All animal studies were approved by the 
Animal Care and Use Committee of the University of Kansas in accordance with the 
National Institutes of Health guidelines for animal care. Five to ten male mice were used per 
group.
Induction of type 1 diabetes
After being fasted for five hours, insulin-deficient diabetes was induced in 3 month-old mice 
by intraperitoneal (i.p.) injection of streptozotocin (STZ, Sigma, St. Louis, MO; dose 60 
mg/kg dissolved in 100 mM citric acid, pH 4.5) on 5 consecutive days. Hyperglycemia was 
confirmed using a strip-operated reflectance meter on a blood sample from tail prick 2 
weeks after STZ injection and in another sample collected after the study (2 to 3 months 
after STZ injection). Citric acid (pH 4.5) was injected as a vehicle control. 0.9% saline 
solution was administered subcutaneously to maintain animal health.
Morris water maze task
Two months following STZ treatment, mice were trained in the Morris water maze. The 
maze is a circular pool of water, maintained at 24 ± 1°C, and divided into imaginary 4 
quadrants. During daily training, an opaque (from white non-toxic paint) platform was 
placed in one of the quadrants and hidden 1 cm below the surface of water. Mice were 
trained to locate the hidden platform during four trials per day over 8 days. Starting points 
were changed every day. For each trial, mouse was allowed to search the platform for 60 s. 
Mice failed to find the platform within 60 s will be guided to the platform and rest for 15 s 
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before next trial. The time required for locating the submerged platform is termed “latency”. 
Twenty-four hours after the last training session on day 8, each animal was given a single 60 
s probe trial. The submerged platform was removed and the animal was expected to enter 
the target quadrant and make more entries into the location that previously contained the 
platform (memory retention). Time spent in the target quadrant, swim speed, and the number 
of entries into the platform location were recorded by video tracking.
Electrophysiological studies
Electrophysiological recordings were performed on coronal hippocampal slices (400 µm in 
thickness), as described [11]. Briefly, the hippocampal slices were recovered at 37°C for at 
least 1 h and then maintained in an interface chamber at 29°C and perfused with artificial 
cerebrospinal fluid (124 mM NaCL, 4.4 mM KCL, 1 mM Na2HPO4, 25 mM NaHCO3, 2 
mM CaCl2, 2.0 mM MgSO4, and 10 mM glucose) continuously bubbled with 95% O2 and 
5% CO2. Field-excitatory post-synaptic potentials (fEPSPs) were recorded for the CA1 
hippocampal region by placing both the stimulating and the recording electrodes in the CA1 
stratum radiatum. Basal synaptic transmission (input-output curve) was assayed by plotting 
the stimulus voltage (V) against the slopes of fEPSPs to generate input-output relations. A 
30 min baseline recording was established using low-frequency stimulation (0.033 Hz; 0.1 
ms impulse duration) and the adjusted intensity that induced fEPSPs with ~30% of the 
maximal fEPSP amplitude. The LTP was induced using theta-burst stimulation (4 pulses at 
100 Hz, with bursts repeated at 5 Hz, and each tetanus, including 3 10-burst trains separated 
by 15 s. Values of the fEPSP slope were expressed as mean ± SEM percentage change 
relative to their mean baseline amplitude.
Immunoblotting analysis
We have performed western blot to determine CypD content in hippocampus homogenates. 
The hippocampi were lysed in cell lysis buffer (Cell signaling #9803; 20 mM Tris-HCl (pH 
7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium 
pyrophosphate) containing protease inhibitor cocktail (Calbiochem, set V, EDTA free). 
Equal amount of proteins were loaded and separated by SDS-PAGE (12% Bis-Tris gel, 
Invitrogen), and then transferred to nitrocellulose membrane (Amersham). Membrane was 
blocked in TBST buffer (20 mM Tris–HCl, 150 mM NaCl, 0.1% Tween-20) containing 5% 
non-fat dry milk (SantaCruz) for 1 h at room temperature, and then incubated and gently 
shaken overnight (at 4°C) with anti-CypD IgG (1:2000, generated in our laboratory) in 
TBST containing 5% non-fat dry milk; this was followed by incubation with corresponding 
secondary antibody for 1 h at room temperature. Chemiluminescence was detected by using 
ECL (GE). The same membrane was stripped and reprobed with antibody to tubulin 
(1:10,000, Sigma) as the protein loading control.
Mitochondrial isolation
Cortical mitochondria were isolated from whole brain cortex of mice as described 
previously [21]. Samples were placed in 9 ml of ice-cold mitochondria isolation buffer [225 
mM mannitol, 75 mM sucrose, 2 mM K2HPO4 (pH 7.2)], and homogenized (10 strokes) 
using a Douce homogenizer (Kontes Glass Co.). Homogenate was centrifuged at 1300 g for 
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5 min at 4°C. The resultant supernatant was then centrifuged at 34,000 g for 10 min after 
layering on 15% Percoll. After centrifugation, the homogenate was resuspended and 
incubated for 5 min on ice in 20 ml of mitochondria isolation buffer with 0.02% digitonin, 
centrifuged at 8,000 g for 10 min. The pellet was washed twice in 1.5 ml mitochondria 
isolation buffer and centrifuges again at 8,000 g for 10 min. The final pellet were 
resuspended in 200ul mitochondria isolation buffer. Total protein concentration of isolated 
mitochondria fraction was determined by Bio-Rad DC protein assay (Bio-Rad Lab).
Mitochondrial oxygen consumption assay
Mitochondrial respiration rate was measured using a Clark oxygen electrode (Oxytherm, 
Hansatech) at with mitochondria kept at 30°C as previously described [21]. Three hundred 
µg mitochondria were added to 1 ml potassium buffer. State 3 respiration was triggered by 
the addition of 150 µM adenosine diphosphate (ADP) in the presence of 5 mM glutamate 
and 5 mM malate; state 4 respiration is defined as oxygen consumption after ADP has been 
consumed. The respiratory control ratio (RCR) of mitochondria is calculated as state 3/state 
4.
Mitochondrial respiratory chain complex activity measurement
Mitochondrial respiratory chain complex activity was measured using the isolated 
mitochondrial fraction as described before [21, 53, 54]. Briefly, NADH: ubiquinone 
oxidoreductase (COX I) enzyme activity was determined in 25 mM potassium buffer 
containing KCl, Tris-HCl and EDTA (pH 7.4). The change in absorbance was monitored at 
340 nm wavelength every 20 sec for 6 min using an Amersham Bio-sciences Ultrospect 
3100 pro spectrophotometer. In the presence of mitochondria (50 µg protein), 2 µg/ml 
antimycin, 5 mM magnesium chloride, 2 mM potassium cyanine and 65 µM co-enzymes Q1 
were added and the oxidation of NADH was recorded for 3 min; then 2 µg/ml rotenone was 
added and absorbance was measured for another 3 min. For measurement of cytochrome c 
oxidase (COX IV) enzyme activity, mitochondrial samples (50 µg protein) were gently 
added to a cuvette containing 0.95 mL of 1× assay buffer (10 mM Tris-HCl, and 120 mM 
potassium chloride, pH 7.0), and the reaction volume was brought to 1.05mL with the 
addition of 1× enzyme dilution buffer (10 mM Tris-HCl, pH 7.0). The reaction was then 
initiated by addition of 50 µL of ferrocy-tochrome substrate solution (0.22 mM). The change 
in absorbance of cytochrome c at 550 nm was measured using a kinetic program with a 5-s 
delay, 10-s interval and a total of 6 readings on an Amersham Biosciences Ultrospect 3100 
pro spectrophotometer. Non-enzymatic background was measured in the sample without the 
isolated mitochondrial fraction.
Data analysis
Data are presented as mean ± SEM. Statistics analyses were performed using Statview 
software (SAS Institute). One-way ANOVA was followed by individual post hoc Fisher 
tests for statistical comparison. p≤ 0.05 was considered statistically significant.
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Experimental induction of type 1 diabetes in mAβPP and nonTg mice
Mice, which were injected with STZ (60 mg/kg i.p.) after five hours of fasting for five 
successive days, exhibited hyperglycemia (blood sugar >250 mg/dl) 2 weeks after initiation 
of STZ injection (339.07 ± 50.9 mg/dl in nonTg/STZ mice and 342.88 ± 36.2 mg/dl in 
mAβPP/STZ mice, Fig. 1A). Two months later, blood glucose levels for diabetic mice 
remained significantly high in both mAβPP (498.09 ± 33.5 mg/dl) and nonTg (517.09 ± 27.6 
mg/dl) mice (Fig. 1A). All mice maintained a healthy weight over the 2-month period (Fig. 
1B). Mice injected with vehicle gained a small amount of weight over the 2-month period. 
Mice with induced diabetes lost weight, but the body weight loss was not significantly 
different between mAβPP (−6.30 ± 1.4 g) and nonTg (−5.79 ± 1.0 g) diabetic animals (p > 
0.05, Fig. 1B). These results confirm that both nonTg and mAβPP mice developed type 1 
diabetes with hyperglycemia as early as 2 weeks after STZ treatment and the resultant 
hyperglycemia was sustained more than 2 months post STZ injection.
Expression of CypD in diabetic and non-diabetic nonTg and mAβPP mice
CypD is a necessary component of mPTP formation, triggering the opening of mPTP by 
translocation of CypD to the inner membrane of mitochondria and causes oxidative stress. 
Previously, we observed up-regulation of CypD in mAβPP mice as compared to nonTg mice 
at the age of 6–12 months [11]. It is also demonstrated that CypD-mediated mPTP opening 
in face to high-fat diet treatment causes mitochondrial dysfunction and insulin resistance in 
skeletal muscle [55]. Therefore, it is possible that diabetes exaggerates CypD upregulation 
in the mAβPP mouse brain. In the present study, we compared CypD levels in mAβPP mice 
to nonTg mice when made diabetic. According to immunoblotting analysis, CypD levels in 
non-diabetic mAβPP or diabetic nonTg hippocampus were significantly increased as 
compared to non-diabetic nonTg controls (Fig. 2, p < 0.05). When mAβPP mice rendered to 
STZ-induced type 1 diabetes, the CypD expression was further increased significantly (Fig. 
2, p < 0.05 versus mAβPP/Vehicle or nonTg/STZ mice).
Increased brain mitochondrial dysfunction in diabetic mAβPP mice
Since mitochondria are vulnerable to changes in glucose homeostasis in diabetes and play a 
critical role in AD progression, we investigated whether experimentally induced type 1 
diabetes exacerbated mitochondrial dysfunction in relatively young transgenic AD mice 
(before onset of clinically observable symptoms) with otherwise normal mitochondrial 
function. Mitochondrial respiration is critical for energy metabolism, cell functioning and 
survival. Decreased mitochondrial respiratory function indicates severe damage to 
mitochondria. We first analyzed mitochondrial respiration by measuring ADP-stimulated 
RCR. During the consumption of 150 µM ADP, STZ-treated nonTg mice (nonTg/STZ) 
cortical mitochondria showed decreased RCR as compared to that found in vehicle-treated 
nonTg (nonTg/Vehicle mitochondria (Fig. 3A). With vehicle treatment, mAβPP cortical 
mitochondria showed compromised RCR (4.92±0.1 in mAβPP/Vehicle mice, p<0.05 versus 
nonTg/Vehicle, Fig. 3A) compared to nonTg/Vehicle mitochondria. While the RCR was not 
significantly different between nonTg/STZ and mAβPP/Vehicle mitochondria (p > 0.5), 
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STZ-induced diabetic mAβPP mice had a significant reduction in RCR compared to vehicle-
treated mAβPP mice (p < 0.05, Fig. 3A).
Cytochrome c oxidase (COX IV) activity was not significantly different when comparing 
nonTg/ Vehicle, nonTg/STZ and mAβPP/Vehicle mice (82.60 ± 2.9 nmol/mg protein/min in 
nonTg/Vehicle, 78.00 ±4.7 nmol/mg protein/min in nonTg/STZ, 81.17 ±3.5 nmol/mg 
protein/min in mAβPP/Vehicle mice, respectively, p>0.05, Fig. 3B). However, mAβPP/STZ 
mitochondria showed a significantly decreased COX IV activity compared to non-diabetic 
mAβPP mitochondria (64.20 ±8.0 nmol/mg protein/min in mAβPP/STZ mice, p<0.05, Fig. 
3B). Compared to vehicle-treated nonTg mice (202.32 ±21.5 nmol/mg protein/min), COX I 
(NADH: ubiquinone oxidoreductase) activity was not significantly altered in nonTg/STZ 
(201.38 ± 31.1nmol/mg protein/min) or mAβPP/Vehicle (197.42 ±26.9 nmol/mg protein/
min) mice (p>0.05, Fig. 3C). In contrast, STZ-mAβPP mice had markedly decreased COX I 
activity (by 50–60%) compared to non-diabetic mAβPP mitochondria (p < 0.01, Fig. 3C).
Taken together, these data indicated that the mitochondrial respiration was impaired in STZ-
induced diabetic nonTg mice (Fig. 3A) while COX I and COX IV activity remained 
unchanged (Fig. 3B–C). As reported previously [21], mAβPP mice at six to seven months of 
age had reduced RCR (Fig. 3A) but no detectable alterations in COX I or COX IV (Fig. 3B–
C). Intriguingly, the young mAβPP mice with experimentally induced type 1 diabetes (STZ 
injection starting at three to four months of age) of two to three months duration showed 
early deficits in mitochondrial respiration and decline in both COX I and COX IV activity 
(Fig. 3).
Early deficit in synaptic plasticity in diabetic mAβPP mice
Given that mitochondria are vital for maintenance of synaptic function and transmission, we 
examined synaptic transmission under basal conditions, paired-pulse facilitation (PPF, a 
form of short-term synaptic plasticity), and during long-term potentiation (LTP, a form of 
synaptic plasticity that is widely studied as a cellular model for learning and memory). 
Consistent with previous observations [23, 29, 30], fEPSPs in the CA1 stratum radiatum 
revealed no alterations in basal synaptic transmission (BST) and PPF in nondiabetic and 
diabetic nonTg mice (p > 0.05 nonTg/Vehicle versus nonTg/STZ, Fig. 4A–B). Compared to 
vehicle-treated nonTg mice, mAβPP/Vehicle mice showed no significant difference in BST 
and PPF at 6–7 months of age (p > 0.05 mAβPP/Vehicle versus nonTg/Vehicle, Fig. 4A–B) 
until 10–12 month of age [11, 16, 56]. CA1 region hippocampal LTP was significantly 
decreased in diabetic nonTg mice (143.07 ±5.1%) compared to non-diabetic nonTg mice 
(209.41 ± 12.5%,p < 0.01, Fig. 4C–D). However, diabetic mAβPP mice had significantly 
reduced hippocampal LTP compared to non-diabetic mAβPP mice (112.22 ± 5.9%, p< 0.01 
versus mAβPP/Vehicle and p < 0.05 versus nonTg/STZ, respectively, Fig. 4C–D). Young (6 
to 7 months of age) vehicle-treated mAβPP mice had normal LTP (196.20 ± 12.9%) 
(p>0.05, mAβPP/Vehicle versus nonTg/Vehicle, Fig. 4C–D). Young diabetic mAβPP mice 
had no changes in BST or PPF (p > 0.05 mAβPP/Vehicle versus mAβPP/STZ, Fig. 4A, B). 
These data demonstrate an early deficit in synaptic dysfunction in diabetic mAβPP mice, 
suggesting that type 1 diabetes worsens synaptic damage in the early stage AD brain, 
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possibly due to deleterious effects of diabetes on mitochondrial respiratory function and 
enzyme activity.
Learning and memory impairments were further aggravated in diabetic mAβPP mice
Behavioral change is a functional manifestation of mitochondrial dysfunction and synaptic 
injury. Previous studies showed that hippocampus is particularly susceptible to diabetes-
induced spatial learning and memory impairment [23, 29] due to synaptic plasticity deficit. 
Similarly, hippocampus-dependent cognitive deficits have been reported in transgenic 
mAβPP mice, which from the age of six months to 22–24 months [11]. We next assessed the 
synergistic effects of type 1 diabetes on learning and memory in young mAβPP mice. We 
evaluated spatial learning and memory in mice at age of six to seven months using a Morris 
water maze as previously described [11, 20]. Vehicle-treated nonTg mice showed good 
learning and memory during the training session (Fig. 5A). mAβPP mice treated with 
vehicle or STZ-treated nonTg mice required a longer time (higher latency) to locate the 
hidden platform during trials (Fig. 5A), indicating impaired spatial learning and memory. 
Notably, STZ-treated mAβPP mice had the longest latency to find the hidden platform (Fig. 
5A).
In the memory retention test, both nonTg/STZ mice (33.16 ±2.6% time in the target 
quadrant, and 2–3 crosses to the platform location) and mAβPP/Vehicle mice (23.80 ± 1.9% 
time in the target quadrant, and 1–2 crosses to the platform location) displayed memory 
deficit compared to nonTg/Vehicle mice (45.56 ± 1.2% time in the target quadrant, and 4–5 
crosses to the platform location) (p<0.01, Fig. 5B, C). Similarly, memory retention was 
further impaired (11.88 ± 3.3% time in the target quadrant, and 0–1 crosses to the platform 
location) in diabetic mAβPP mice (p<0.01 mAβPP/Vehicle versus mAβPP/STZ, Fig. 5B, C). 
We did not find any significant difference in swimming speed in the four groups of mice 
(Fig. 5D). These data demonstrate that diabetes accelerates cognitive dysfunction in AD 
mice.
DISCUSSION
There is growing evidence of links between AD and diabetes [43–46]. Aged patients with 
diabetes are at increased risk for AD [47]. While experimental induction of diabetes in 
mouse models of AD exacerbates features of AD, including increased Aβ formation and 
accumulation [46, 48–50], tau phosphorylation [46, 48, 50], and learning and memory 
deficit [46, 48–50], the underlying mechanisms are unclear. Mitochondria are particularly 
affected by hyperglycemia in diabetes [31–38] and mitochondrial and synaptic dysfunction 
is an early pathological feature of AD-affected brain, playing a critical role in AD 
progression [3–15]. Therefore, the two diseases might share a common mitochondria-related 
mechanism that leads to brain dysfunction. In the present study, we induced type 1 diabetes 
in mAβPP transgenic mice to test whether mitochondrial perturbation secondary to diabetes 
contributes to AD progression. Indeed, experimental induction of type 1 diabetes accelerated 
mitochondrial defects and exacerbated impairments in synaptic plasticity and spatial 
learning and memory in mAβPP mice at 6–7 month old age.
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CypD is a key component of mPTP Oxidative and other cellular stresses promote CypD 
translocation to the inner membrane [57–62], which in turn triggers opening the mPTP 
leading to cell death. Low expression of CypD in brain mitochondria increases resistance of 
mPTP induced by calcium [63], whereas high levels of CypD in neuronal mitochondria 
result in their greater vulnerability to the opening of mPTP and require higher levels of 
cyclosporin A (an inhibitor of CypD) to inhibit mPTP opening [64]. Consistent with these 
observations, genetic deficiency in CypD protects cells against Ca2+-, oxidative stress-, or 
Aβ-induced cell death [61, 65–67]. CypD has been reported to play a vital role in both AD-
induced brain dysfunction [11, 20, 68] and diabetes-induced peripheral organs damages such 
as heart [69, 70] and skeletal muscle [55]. In our present study, we found that CypD 
expression levels were significantly elevated in hippocampus of STZ-induced diabetic 
nonTg mice as compared to vehicle-nonTg mice (Fig. 2, p < 0.05). When mAβPP mice were 
subjected to STZ-induced type 1 diabetes, the CypD expression was further increased 
significantly in hippocampus of diabetic mAβPP mice as compared with non-diabetic 
mAβPP mice (Fig. 2, p < 0.05 versus mAβPP/Vehicle or nonTg/STZ mice). These data 
suggested that CypD expression level was increased in diabetes mellitus and further 
enhanced in an Aβ-enriched environment. Increased amount of CypD in mitochondria would 
trigger/enhance the opening of mPTP, which leads to colloid osmotic swelling of the 
mitochondrial matrix, dissipation of the inner membrane potential (∆Ψm), accumulation/
generation of reactive oxygen species, and the release of many pro-apoptogenic proteins and 
procaspases [71–75]. Indeed, our previous studies demonstrated an upregulation of CypD in 
non-diabetic mAβPP mice as compared to nonTg mice at the age of 6–12 months [11]. 
CypD-deficiency in AD mice overexpressing human A β protected from Aβ-induced 
mitochondrial oxidative stress, increased capacity of mitochondrial calcium uptake, 
improved synaptic function, and ameliorated cognitive deficits [11, 20]. Additionally, 
CypD-mediated mPTP opening in face to high-fat diet treatment causes mitochondrial 
dysfunction and insulin resistance in skeletal muscle [55]. Therefore, CypD-mediated mPTP 
opening may be one of the mechanisms for diabetes-accelerated mitochondrial dysfunction 
in AD brain, which could ultimately contribute to synaptic injury and cognitive deficits in 
diabetic AD mice. Other mPTP components such as the voltage dependent anion channel 
[76] in the outer membrane and the adenine nucleotide translocase in the inner membrane 
may also contribute importantly to mitochondrial dysfunction in diabetes mellitus. The 
detailed mechanistic studies relevant to mPTP in diabetes are required for the further 
investigation.
Mitochondrial dysfunction is known to play an important mechanistic role in both diabetes 
and AD. Mitochondrial respiration is the most important function of mitochondria and 
healthy respiratory function is required for normal mitochondrial function. While no 
significant alterations were observed in COX I or COX IV activity, decreased mitochondrial 
RCR in cortical mitochondria of diabetic nonTg and non-diabetic mAβPP littermates 
suggest impaired mitochondrial function. Early mitochondrial respiratory rate decline and 
impaired COX I and COX IV activity in cortical mitochondria from STZ-induced diabetic 
mAβPP mice suggest that type1 diabetes exaggerates mitochondrial dysfunction at the early 
stage AD. Because respiratory chain reflects electron flux through complexes I, III, and IV, 
inactivation of enzyme activities associated with anyone/or all of these complexes in the 
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respiratory chain could disturb the respiratory chain function, leading to decreased oxygen 
consumption. Thus, reduced complex I and IV activity could be the mechanism for 
perturbing mitochondrial respiratory chain function observed in diabetic mAβPP mice.
Mitochondria are essential for synaptic function by providing energy and regulating intra-
synaptic metabolic homeostasis [51, 52]. Damaged mitochondria in diabetic mAβPP mice 
are associated with synaptic injury. Consistent with previous reports [23, 29, 30], we 
observed LTP impairment in hippocampal CA1 region of STZ-treated animals. The LTP 
defect was significantly exacerbated in diabetic mAβPP mice though there was no 
significant synaptic plasticity deficit in young (6–7 month of age) mAβPP littermates, 
suggesting an accelerated AD progression with diabetes insult.
Decreased mitochondrial and synaptic function in diabetic young mAβPP mice is associated 
with a poor performance on the Morris water maze, reflecting impaired memory formation 
and retention. These differences in performance are not due to decreased swim speed, 
thereby excluding systemic consequences such as weight loss. We observed mildly impaired 
spatial learning and memory in diabetic nonTg mice compared to non-diabetic controls (Fig. 
5). STZ-induced diabetic mAβPP mice experienced significantly enhanced cognitive decline 
compared to non-diabetic mAβPP mice. Thus, diabetes may be an exacerbating factor, at 
least in part, for AD-associated changes in learning and memory, especially in early stage 
AD.
Another potential mechanism underlying diabetes-induced mitochondrial and synaptic 
dysfunction in mAβPP mice may root in potentiated Aβ production, in parallel to the 
enhanced CypD expression. In our present study, Aβ40 and Aβ42 levels were significantly 
increased in mAβPP mice with and without STZ treatment compared to STZ-treated nonTg 
mice. However, no significant differences of Aβ levels were found between STZ-mAβPP 
and vehicle-mAβPP mice (data not shown). These results are consistent with previous 
studies showing no effect on Aβ production in either STZ-injected mAβPP/PS1 mice (AβPP/
Ps1-STZ mice) [49] or leptin-deficient mAβPP subjects (mAβPP-ob/ob mice) [77]. Using 
high-fat diet-induced aging mouse model, A β levels were increased in brain of high-fat diet-
induced senescence-accelerated SAMP8 mice (HF-SAMP8 mice) [50]. In addition, 
increasing evidence demonstrate that induction of chronic diabetes in transgenic mouse 
model of AD (in both HF-SAMP8 and mAβPP-ob/ob mice) increases Aβ accumulation in 
brain microvascular vessels [46, 77]. These studies suggest the close relationship of the 
chronic diabetes with A β accumulation. Our recent preliminary results showed a significant 
increased cerebellar Aβ level in brain of type 2 diabetes mouse model (DB/DB mice, data 
not shown). Nevertheless, up-regulation of CypD expression in diabetic AD mouse brain 
could be a link of mitochondrial perturbation to synaptic and cognitive dysfunction in an 
early stage of AD progression.
In summary, we provide evidence that diabetes-mediated mitochondrial perturbation is 
linked to synaptic dysfunction as well as learning and memory deficit, contributing to the 
early stage AD progression. Hyperglycemia may accelerate the onset of neurochemical 
indices of CNS damage in AD pathogenesis. Our results clearly revealed that CypD was 
elevated in hippocampus when mice were rendered to experimental induction of type 1 
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diabetes. Intriguingly, there is a synergistic exacerbation of hippocampal CypD upregulation 
in diabetes and diabetic AD mice. Such modulation of CypD expression may be one of the 
mechanisms for diabetes-accelerated mitochondrial dysfunction in AD brain, which could 
ultimately contribute to synaptic injury and cognitive deficits when superimposed with Aβ 
toxicity. Thus, preserving mitochondrial function may be beneficial in halting 
hyperglycemia-associated AD progression. Although many differences exist, some features 
such as hyperglycemia are common in both type1 and type 2 diabetes. Given that type 2 
diabetes is more common in patients, it will be highly interest of understanding the role and 
regulation of brain mitochondria in CNS complications of type 2 diabetes as well.
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Blood glucose and body weight of vehicle-treated nontransgenic (nonTg/Vehicle), diabetic 
nonTg (nonTg/STZ), vehicle-treated mAβPP (mAβPP/Vehicle), and diabetic mAβPP (mA|
3PP/STZ) mice before and after induction of diabetes. A) Blood glucose levels before 
treatment (baseline), 2 weeks after STZ injection (2 weeks) and >2 months after STZ 
injection in the indicated groups of mice. B) Body weight changes in the indicated groups of 
mice before (open bar) and after 2 months of STZ treatment (Black filled bar). *p <0.01 
nonTg/Vehicle versus nonTg/STZ, and # p <0.01 mAβPP/Vehicle versus mAβPP/STZ. n = 
5–10 per group.
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Expression of CypD in diabetic and non-diabetic nonTg and mAβPP mice. Densitometry of 
CypD immunoreactive bands in the indicated groups of mice using NIH imageJ program 
(upper panel; n = 5 mice per group; p<0.05). Lower panel shows representative images of 
immunoblots for CypD and tubulin (used as a protein loading control showing an equal 
amount of protein added to each lane). *p<0.05 nonTg/STZ or mAβPP/Vehicle versus 
nonTg/Vehicle, $p<0.05 mAβPP/STZ versus nonTg/STZ and #p<0.01 mAβPP/Vehicle 
versus mA|3PP/STZ. n = 5 mice per group.
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Effect of STZ-induced diabetes on mitochondrial respiratory function and complex I and IV 
enzyme activity in transgenic mAβPP mice and nonTg littermates. Respiration control ratio 
(RCR) (A), cytochrome c oxidase activity (B), and NADH: ubiquinone oxidoreductase (C) 
in cortical mitochondria from the indicated mice at 6–7 months of age. *p<0.01 nonTg/
Vehicle versus nonTg/STZ, # p<0.05 mAβPP/Vehicle versus mAβPP/STZ, and $p < 0.05 
mAβPP/STZ versus nonTg/STZ. n = 4–5 mice per group.
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Effect of STZ-induced diabetes on basal synaptic transmission (BST), paired-pulse 
facilitation (PPF) and long term potentiation (LTP) in transgenic mAβPP mice and nonTg 
littermates. A) BST, field-excitatory post-synaptic potentials (fEPSPs) plotted against 
stimulation intensity; and (B) PPF, the ratio of send pulse-induced fEPSPs to the first pulse-
elicited fEPSPs, did not differ among indicated groups. C) Hippocampal LTP was recorded 
in the indicated groups for mice 6–7 months. Slices from 6–7 month-old mAβPP mice 
treated with vehicle showed no significant LTP reduction compared to nonTg/Vehicle slices. 
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However, experimental induction of type1 diabetes mAβPP and nonTg mice resulted in 
reduced impairment of hippocampal LTP. Note, LTP levels were almost completely 
abolished in mAβPP/STZ mice. D) LTP amplitudes among the indicated groups of mice 
were calculated by an average of fEPSP slopes during 50–60 minutes after theta burst 
stimulation. *p<0.01 nonTg/Vehicle versus nonTg/STZ, #p < 0.01 mAβPP/Vehicle versus 
mAβPP/STZ, and $p < 0.05 mAβPP/STZ versus nonTg/STZ. n = 9–14 per group from 5–6 
mice.
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Effect of STZ-induced diabetes on spatial learning and memory in transgenic mAβPP mice 
and nonTg littermates. Mice were tested in a Morris water maze at the age of 6–7 month-
old. A) Escape latencies in hidden-platform during training in indicated groups. Time spent 
in target quadrant (B), number of annulus crossings (C), and swimming speed (D) are 
shown. Learning and memory are impaired in diabetic nonTg and nondiabetic mAβPP mice. 
Learning and memory deficits were exacerbated in mAβPP mice following induction of 
diabetes. “Target” indicates the area where the platform was located in the hidden-platform 
training session. *p < 0.01 nonTg/Vehicle versus nonTg/STZ, #p < 0.01 mAβPP/Vehicle 
versus mAβPP/STZ, and $p < 0.05 mAβPP/STZ versus nonTg/STZ. n = 6–8 per group.
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